低剂量免疫治疗在头颈癌中的随机研究
在资源有限地区,晚期头颈鳞癌患者难以负担标准方案。本随机III期优效性研究将151例患者按1:1分配至三联节拍化疗(TMC)或TMC联合低剂量纳武利尤单抗(TMC-I)。联合组1年总生存率从16.3%提高至43.4%(HR 0.545,P=0.0036),中位总生存从6.7个月延长至10.1个月,3级及以上不良事件发生率两组相似。
要点
- TMC-I组1年OS为43.4%,TMC组为16.3%(HR 0.545,P=0.0036)。
- TMC-I组中位OS为10.1个月,TMC组为6.7个月(P=0.0052)。
- 两组3级及以上不良事件发生率分别为46.1%和50%(P=0.744)。
核心结论
- 在节拍化疗基础上加用低剂量纳武利尤单抗可改善总生存,可作为无法获得全剂量检查点抑制剂患者的替代标准治疗。
研究设计与样本
- 随机III期优效性研究,纳入151例复发或新诊断的晚期头颈鳞癌成人患者,按1:1随机分配至TMC组(75例)或TMC-I组(76例)。
主要发现
- TMC-I组1年OS为43.4%(95%CI 30.8-55.3),TMC组为16.3%(95%CI 8.0-27.4),HR 0.545(95%CI 0.362-0.820),P=0.0036。
- TMC-I组中位OS为10.1个月(95%CI 7.4-12.6),TMC组为6.7个月(95%CI 5.8-8.1),P=0.0052。
- TMC-I组3级及以上不良事件发生率为46.1%,TMC组为50%,P=0.744。
关键数值与推荐
- TMC方案:口服甲氨蝶呤9 mg/m2每周一次,塞来昔布200 mg每日两次,厄洛替尼150 mg每日一次。
- TMC-I方案:在TMC基础上加用静脉纳武利尤单抗20 mg固定剂量,每3周一次。
临床怎么用
- 作者认为,对于无法获得全剂量检查点抑制剂的患者,低剂量纳武利尤单抗联合节拍化疗是替代标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting. Retrospective data suggest that a low dose of nivolumab may be efficacious. Hence, we aimed to assess whether the addition of low-dose nivolumab to triple metronomic chemotherapy (TMC) improved overall survival (OS). METHODS: This was a randomized phase III superiority study. Adult patients with recurrent or newly diagnosed advanced head and neck squamous cell carcinoma being treated with palliative intent with an Eastern Cooperative Oncology Group performance status of 0-1 were eligible. Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m2 once a week, celecoxib 200 mg twice daily, and erlotinib 150 mg once daily, or TMC with intravenous nivolumab (TMC-I) 20 mg flat dose once every 3 weeks. The primary end point was 1-year OS. RESULTS: One hundred fifty-one patients were randomly assigned, 75 in TMC and 76 in the TMC-I arm. The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; hazard ratio, 0.545; 95% CI, 0.362 to 0.820; P = .0036). The median OS in TMC and TMC-I arms was 6.7 months (95% CI, 5.8 to 8.1) and 10.1 months (95% CI, 7.4 to 12.6), respectively (P = .0052). The rate of grade 3 and above adverse events was 50% and 46.1% in TMC and TMC-I arms, respectively (P = .744). CONCLUSION: To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.
引用
- Patil VM, Noronha V, Menon N, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol. 2022. PMID: 36265101. doi:10.1200/JCO.22.01015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。